Pazhanichamy Kalailingam

Dr. Pazhanichamy Kalailingam

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2023 in EMBO Molecular Medicine
Verified
Journal Article
Open access
Pazhanichamy KalailingamPazhanichamy Kalailingam
Pazhanichamy Kalailingam
KMKhalilatul‐Hanisah Mohd‐Kahliab
Khalilatul‐Hanisah Mohd‐Kahliab
SNSoFong Cam Ngan
SoFong Cam Ngan
RIRanjith Iyappan
Ranjith Iyappan
EMEvelin Melekh
Evelin Melekh
SSSiu Kwan Sze
Siu Kwan Sze
Aging results from the accumulation of molecular damage that impairs normal biochemical processes. We previously reported that age‐linked damage to amino acid sequence NGR (Asn‐Gly‐Arg) results in “gain‐of‐function” conformational switching to isoDGR (isoAsp‐Gly‐Arg). This integrin‐binding motif activates leukocytes and promotes chronic inflammation, which are characteristic features of age‐linked cardiovascular disorders. We now report that anti‐isoDGR immunotherapy mitigates lifespan reduction of Pcmt1 −/− mouse. We observed extensive accumulation of isoDGR and inflammatory cytokine expression in multiple tissues from Pcmt1 −/− and naturally aged WT animals, which could also be induced via injection of isoDGR‐modified plasma proteins or synthetic peptides into young WT animals. However, weekly injection of anti‐isoDGR mAb (1 mg/kg) was sufficient to significantly reduce isoDGR‐protein levels in body tissues, decreased pro‐inflammatory cytokine concentrations in blood plasma, improved cognition/coordination metrics, and extended the average lifespan of Pcmt1 −/− mice. Mechanistically, isoDGR‐mAb mediated immune clearance of damaged isoDGR‐proteins via antibody‐dependent cellular phagocytosis (ADCP). These results indicate that immunotherapy targeting age‐linked protein damage may represent an effective intervention strategy in a range of human degenerative disorders.

5 January 2025 in Aging Cell
Verified
Journal Article
Open access
Pazhanichamy KalailingamPazhanichamy Kalailingam
Pazhanichamy Kalailingam
SNSoFong Cam Ngan
SoFong Cam Ngan
RIRanjith Iyappan
Ranjith Iyappan
ANAfra Nehchiri
Afra Nehchiri
KMKhalilatul‐Hanisah Mohd‐Kahliab
Khalilatul‐Hanisah Mohd‐Kahliab
SSSiu Kwan Sze
Siu Kwan Sze
Accumulation of damaged biomolecules in body tissues is the primary cause of aging and age‐related chronic diseases. Since this damage often occurs spontaneously, it has traditionally been regarded as untreatable, with typical therapeutic strategies targeting genes or enzymes being ineffective in this domain. In this report, we demonstrate that an antibody targeting the isoDGR damage motif in lung tissue can guide immune clearance of harmful damaged proteins in vivo, effectively reducing age‐linked lung inflammation. We observed age‐dependent accumulation of the isoDGR motif in human lung tissues, as well as an 8‐fold increase in isoDGR‐damaged proteins in lung fibrotic tissues compared with healthy tissue. This increase was accompanied by marked infiltration of CD68+/CD11b + macrophages, consistent with a role for isoDGR in promoting chronic inflammation. We therefore assessed isoDGR function in mice that were either naturally aged or lacked the isoDGR repair enzyme. IsoDGR‐protein accumulation in mouse lung tissue was strongly correlated with chronic inflammation, pulmonary edema, and hypoxemia. This accumulation also induced mitochondrial and ribosomal dysfunction, in addition to features of cellular senescence, thereby contributing to progressive lung damage over time. Importantly, treatment with anti‐isoDGR antibody was able to reduce these molecular features of disease and significantly reduced lung pathology in vivo.

11 April 2022 in Biology
Verified
Journal Article
Open access
PDF file
Yat Joong ChungYat Joong Chung
Yat Joong Chung
ASAmrita Salvi
Amrita Salvi
Pazhanichamy KalailingamPazhanichamy Kalailingam
Pazhanichamy Kalailingam
MAMyra Alnawaz
Myra Alnawaz
STSuat Hoon Tan
Suat Hoon Tan
TTThirumaran Thanabalu
Thirumaran Thanabalu
Neural Wiskott–Aldrich Syndrome Protein (N-WASP) regulates actin cytoskeleton remodeling. It has been known that reduced N-WASP expression in breast and colorectal cancers is associated with poor prognosis. Here, we found reduced N-WASP expression in squamous cell carcinoma (SCC) patient samples. The SCC cell line HSC-5 with reduced N-WASP expression was used to generate HSC-5CN (control) and HSC-5NW (N-WASP overexpression) cells. HSC-5NW cells had reduced cell proliferation and migration compared to HSC-5CN cells. HSC-5NW cells had increased phospho-ERK2 (extracellular signal-regulated kinase 2), phosphorylated Forkhead box protein class O1 (FOXO1) and reduced nuclear FOXO1 staining compared to HSC-5CN cells. Proteasome inhibition stabilized total FOXO1, however, not nuclear staining, suggesting that FOXO1 could be degraded in the cytoplasm. Inhibition of ERK2 enhanced nuclear FOXO1 levels and restored cell proliferation and migration of HSC-5NW to those of HSC-5CN cells, suggesting that ERK2 regulates FOXO1 activity. The expression of thioredoxin-interacting protein (TXNIP), a FOXO1 target that inhibits thioredoxin and glucose uptake, was higher in HSC-5NW cells than in HSC-5CN cells. Knockdown of TXNIP in HSC-5NW cells restored cell proliferation and migration to those of HSC-5CN cells. Thus, we propose that N-WASP regulates cell proliferation and migration via an N-WASP-ERK2-FOXO1-TXNIP pathway.

7 September 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Pazhanichamy KalailingamPazhanichamy Kalailingam
Pazhanichamy Kalailingam
AVApoorva Verma
Apoorva Verma
YLYing Hui Lee
Ying Hui Lee
TTThirumaran Thanabalu
Thirumaran Thanabalu
Squamous cell carcinoma (SCC) is one of the most common forms of skin cancer in humans, and Neural Wiskott-Aldrich Syndrome Protein (N-WASP) plays a crucial role in epidermal homeostasis. To elucidate the role of N-WASP in skin cancer, we generated mice which expressed constitutively active KRas (KRasG12D) in keratinocytes with either homozygous (N-WASPKOG12D) or heterozygous (N-WASPHetG12D) N-WASP knockout upon Tamoxifen (TAM) injection. Both the N-WASPKOG12D and N-WASPHetG12D mice had similar body weights and no congenital malformations prior to the injection of TAM. Within 2 weeks of the injections, the N-WASPKOG12D mice exhibited significant reductions in weight coupled with visible tumors at numerous sites, unlike the N-WASPHetG12D mice, which had no visible tumors. We found that both sets of mice had oily, sticky skin and wet eyes 3 weeks after their exposure to TAM, indicating the overproduction of sebum/meibum. At 37 days post TAM injection, several notable observations were made. Tumors collected from the N-WASPKOG12D mice had small- to large-sized keratin pearls that were not observed in the N-WASPHetG12D mice. A Western blot and immunostaining analysis both highlighted significantly higher levels of expression of SCC markers, such as the cytokeratins 8, 17, 18, and 19 and TP63, in the tumors of the N-WASPKOG12D mice compared to those of the latter group. Furthermore, we noted increases in the expression levels of EGFR, P-ERK, GLUT1, P-mTOR, and P-4EBP in the N-WASPKOG12D mice, suggesting that the deletion of N-WASP in the keratinocytes enhanced KRas signaling and glucose uptake, resulting in aggressive tumor formation. Interestingly, a thickening of the epidermal layer within the esophagus and tongue was only observed in the N-WASPKOG12D mice. Immunostaining for PCNA emphasized a significantly higher number of PCNA-positive cells in the skin of the N-WASPKOG12D mice compared to their counterparts, implying that epidermal thickening and enhanced tumorigenesis are due to an increased proliferation of keratinocytes. Through our results, we have established that N-WASP plays a tumor-suppressive role in skin cancer.

11 November 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
CAChristiano R. R. Alves
Christiano R. R. Alves
SDSabyasachi Das
Sabyasachi Das
VKVijai Krishnan
Vijai Krishnan
LHLeillani L. Ha
Leillani L. Ha
LFLauren R. Fox
Lauren R. Fox
PMPatricia L. Musolino
Patricia L. Musolino
Genetic vascular disorders are prevalent diseases that have diverse etiologies and few treatment options. Pathogenic missense mutations in the alpha actin isotype 2 gene ( ACTA2 ) primarily affect smooth muscle cell (SMC) function and cause multisystemic smooth muscle dysfunction syndrome (MSMDS), a genetic vasculopathy that is associated with stroke, aortic dissection, and death in childhood. Here, we explored genome editing to correct the most common MSMDS-causative mutation ACTA2 R179H. In a first-in-kind approach, we performed mutation-specific protein engineering to develop a bespoke CRISPR-Cas9 enzyme with enhanced on-target activity against the R179H sequence. To directly correct the R179H mutation, we screened dozens of configurations of base editors (comprised of Cas9 enzymes, deaminases, and gRNAs) to develop a highly precise corrective A-to-G edit with minimal deleterious bystander editing that is otherwise prevalent when using wild-type SpCas9 base editors. We then created a murine model of MSMDS that exhibits phenotypes consistent with human patients, including vasculopathy and premature death, to explore the in vivo therapeutic potential of this base editing strategy. Delivery of the customized base editor via an engineered SMC-tropic adeno-associated virus (AAV-PR) vector substantially prolonged survival and rescued systemic phenotypes across the lifespan of MSMDS mice, including in the vasculature, aorta, and brain. Together, our optimization of a customized base editor highlights how bespoke CRISPR-Cas enzymes can enhance on-target correction while minimizing bystander edits, culminating in a precise editing approach that may enable a long-lasting treatment for patients with MSMDS.

11 March 2026 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
EKErika Kitajima
Erika Kitajima
ASAshley Suwanda
Ashley Suwanda
DJDan Jobson
Dan Jobson
LALouise Allan
Louise Allan
KPKian Paydar
Kian Paydar
RKRaj N. Kalaria
Raj N. Kalaria
Carotid artery disease (CAD) is a recognised cause of stroke. However, the relationships between CAD, cerebral small vessel disease (SVD) and dementia remain unclear. We hypothesised that CAD in older individuals contributes to cerebral SVD pathology by altering cerebral perfusion. We performed a clinicopathological study in patients from the Cognitive Function After Stroke (CogFAST) study and prospectively recruited patients with various dementia diagnoses and evidence of cerebral SVD. In addition to brain tissues, we collected postmortem samples of the internal carotid arteries (ICA) from these cohorts in the Newcastle Brain Tissue Resource. Standard neuropathological examination was performed for diagnosis and assignment of the cases per current diagnostic criteria for vascular and neurodegenerative dementias, which were assessed for the presence of vascular pathology including the degree of stenosis and sclerosis in vascular tissues. We evaluated a total of 159 ICA samples and brain tissues from all cases with evidence of SVD. Severity of ICA stenosis and sclerotic index correlated strongly with both clinical stroke and brain infarction ( P < 0.001). More than 90% of the subjects had one subtype of ICA lesion in the order: intimal thickening > fibrocalcific > fibrous cap (thick) > fibrous cap (thin) > thrombus group with a strong inflammatory reaction in fibrocalcific atheromas. Regression analyses showed that ICA stenosis was positively correlated to both SVD pathology scores ( P < 0.034) and the total number of vascular lesions ( P < 0.001). ICA stenosis was also related to dementia caused by cerebrovascular disease ( P < 0.001) and by mixed pathologies characterised by Alzheimer’s disease and SVD ( P = 0.025). Severity of stenosis was related to subcortical and white matter (WM) vascular lesions within the anterior circulation. ICA stenosis and sclerosis were moreover correlated with the total intracranial artery pathology scores ( P < 0.001). In the CogFAST group analysis, we observed that MMSE and CAMCOG scores were lower in subjects with moderate to severe stenosis scores compared to the mild stenosis group ( P < 0.05). In these CogFAST cases, by far the majority of lesions in the WM were small in size (< 5 mm, range 72–91%) but not in the cortex or basal ganglia and thalamus. Linear regression analysis further indicated that there were greater numbers of these small lesions in the WM with increasing severity of ICA stenosis ( P < 0.05). Our observations suggest carotid atherosclerosis promotes cerebral SVD types of change within the intracerebral arteries. It is conceivable that extracranial ICA pathology may influence perfusion and integrity of subcortical structures including the deep WM.